Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson
| Status: | Archived |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | June 2009 |
| End Date: | June 2011 |
Feasibility of Detecting Myocardial Ischemia by First-pass Contrast MRI Using Regadenoson
This is a pilot study to determine whether the drug regadenoson can be used during magnetic
resonance imaging to assess regions of poor blood flow to the heart.
The hypothesis of this study is that a single injection of regadenoson could be used instead
of a standard adenosine infusion to produce coronary vasodilatation and demonstrate
myocardial ischemia during first-pass perfusion cardiac MRI.
This is a pilot study that proposes to assess the feasibility of using regadenoson
(Lexiscan, Astellas), a recently FDA approved A2A receptor agonist, as the stress perfusion
agent in cardiac MRI perfusion examinations. While regadenoson has been approved by the
FDA, it has not been approved for the specific indications of use 1) during the simultaneous
intravenous administration of a gadolinium-based contrast agent, or 2) during magnetic
resonance imaging (MRI).
Because this agent can be given intravenously in a single 400 microgram bolus, rather than
in an infusion, this agent may be easier to administer than adenosine during an MRI
examination.
The objectives for this pilot study are: 1) To demonstrate the feasibility of using
regadenoson during cardiac perfusion MRI to visualize known regions of myocardial ischemia
as demonstrated on SPECT-MPI and 2) To describe a cardiac perfusion MRI protocol using
regadenoson that would have the potential to be used clinically.
We found this trial at
1
site
Washington University Washington University creates an environment to encourage and support an ethos of wide-ranging...
Click here to add this to my saved trials
